chrisvoncsefalvay/vaers-outcomes huggingface dataset:
17 year old received vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old received vaccine) in a 17-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Sep-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old received vaccine). On 27-Sep-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old received vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported. No treatment drug details was reported.   Most recent FOLLOW-UP information incorporated above includes: On 01-Oct-2021: follow up received contains Non significant information.
This case was reported by a consumer via call center representative and described the occurrence of allergy to vaccine in a 77-year-old female patient who received SHINGRIX. Concurrent medical conditions included breast cancer. On 24th April 2018, the patient received SHINGRIX (intramuscular). On 25th April 2018, 1 days after receiving SHINGRIX, the patient experienced allergy to vaccine, nausea, tiredness, shivering and influenza-like symptoms. On 8th May 2018, the patient experienced gas and abdominal distension. SHINGRIX was discontinued. On an unknown date, the outcome of the allergy to vaccine was unknown and the outcome of the nausea, gas, abdominal distension, tiredness, shivering and influenza-like symptoms were not recovered/not resolved. It was unknown if the reporter considered the allergy to vaccine and abdominal distension to be related to SHINGRIX. The reporter considered the nausea, gas, tiredness, shivering and influenza-like symptoms to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX on left deltoid. The patient felt nauseated every afternoon after receiving SHINGRIX and she said that they were halting her physical activity. In 2018, fourteen days after receiving SHINGRIX, the patient's tummy was extended and she had a lot of gas. The patient's physician told her to not have her second dose of SHINGRIX because physician thought she was allergic to the vaccine. The patient said that she was not going to have her second dose of SHINGRIX.
Over 36 days since 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Over 36 days since 1st dose) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jul-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Over 36 days since 1st dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Over 36 days since 1st dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant product use was provided by the reporter. No treatment medication was provided.
Patient requested the Abrexvy RSV vaccine via prescription that was given to him by his nurse practitioner. Patient made an appointment via our digital scheduler and selected the only RSV vaccine we offer at our location which was the Abrysvo RSV vaccine. Patient handed the prescription to the technician the technician thought patient was looking for any RSV vaccine. Patient was processed for the Abrysvo RSV vaccine. Patient is aware of error and so is NP.
?? additional ?? reported; PROQUAD was concomitantly administered with VARIVAX; This spontaneous report was received from a nurse practitioner and refers to a patient of unspecified age and gender. The patient's pertinent medical history, concomitant medications, past drug reactions or allergies were not reported.  On 06-OCT-2021, the patient was vaccinated  with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live rHA (recombinant Human albumin) (PROQUAD) 0.5 milliliter (ml) (lot number T034827 that was verified to be a valid lot number with an expiration date reported and established as 11-APR-2022) and was concomitantly administered with varicella virus vaccine live (Oka/Merck) (VARIVAX) 0.5 milliliter (ml) (lot number U010395 that was verified to be a valid lot number with an expiration date reported and established as 01-APR-2023) for prophylaxis (dose numbers, vaccination scheme frequencies, routes and anatomical sites of administration were not reported) (inappropriate schedule of product administration).  No additional adverse event (no adverse event) was reported.
WEAK AND HEAVY FEELING ON THE FACE; FEELS LIKE THE CIRCULATION IS LOW; WEAKNESS ON THE RIGHT LEG RIGHT ARM AND LEFT FOOT; NUMBNESS ON THE RIGHT LEG RIGHT ARM AND LEFT FOOT; COLD LIMBS; ABDOMINAL PAIN; SORE INJECTION SITE; HEADACHE; NECK PAIN; CLOUDY CLEAR URINE; SWOLLEN VEIN ON RIGHT FOOT; HIGHER BP THAN NORMAL; WEIGHT LOSS; This spontaneous report received from a patient concerned a 59 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included raynaud, and other pre-existing medical conditions included the patient had no known allergies.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808980, expiry: UNKNOWN) dose was not reported, administered on 03-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On APR-2021, the subject experienced abdominal pain. On APR-2021, the subject experienced neck pain. On APR-2021, the subject experienced cloudy clear urine. On APR-2021, the subject experienced swollen vein on right foot. On APR-2021, the subject experienced higher bp than normal. On APR-2021, the subject experienced weight loss. On APR-2021, the subject experienced sore injection site. On APR-2021, the subject experienced headache. On 14-APR-2021, the subject experienced numbness on the right leg right arm and left foot. On 14-APR-2021, the subject experienced cold limbs. On 14-APR-2021, the subject experienced weak and heavy feeling on the face. On 14-APR-2021, the subject experienced feels like the circulation is low. On 14-APR-2021, the subject experienced weakness on the right leg right arm and left foot. On 19-APR-2021, Laboratory data included: CT scan (NR: not provided) No thrombosis findings, and Laboratory test (NR: not provided) No thrombosis finding. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from headache, neck pain, sore injection site, numbness on the right leg right arm and left foot, cold limbs, cloudy clear urine, swollen vein on right foot, abdominal pain, weak and heavy feeling on the face, higher bp than normal, weight loss, weakness on the right leg right arm and left foot, and feels like the circulation is low. This report was non-serious.; Sender's Comments: V0: Medical Assessment comment was not required as per standard procedure as the case assessed as non-serious.
patient received the vaccination indicated for children aged 6-11 instead of the one for 12 and older.
Started a few hours after injection, the patient started to experience adverse symptoms such as GI discomfort, nausea, vomiting, diarrhea, cramps, and body aches. This lasted for about 5 days and have since improved, but are still present.
COMA; This spontaneous report received from a consumer via a company representative via social media concerned multiple (2) patients of an unspecified age, sex, race and ethnicity.   The patient's weight, height, and medical history were not reported. The patients received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number and expiry date were not reported) dose, start therapy date were not reported, 1 total administered for covid-19 prophylaxis. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the patients went into coma. It was reported as "I personally know 2 people that went in a coma from the vaccination". The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of coma was not reported. This report was serious (Other Medically Important Condition). This case, from the same reporter is linked to 20221241346.; Sender's Comments: V0-20221241416- Coma. Insufficient information is available to make a causality assessment. Therefore, this event is considered unclassifiable.
This spontaneous report was received from a currently 74 year old female patient, concerning herself. The patient's medical was not reported. Concurrent conditions included bone marrow disease, glaucoma and breast cancer. The patient was allergic to penicillin, "unspecified sulfa drugs" and preservatives. Concomitant medications included JAKAFI. In Approximately 2010 (reported as "about 7 years ago"), the patient was vaccinated with PNEUMOVAX 23 for prophylaxis (route of administration, lot number and expiration date were not reported), and she experienced, on unspecified dates, some chills and a fever after getting the vaccine for the first time. On 24-OCT-2017, the patient was vaccinated with PNEUMOVAX 23, intramuscularly, for pneumonia prevention (lot number and expiration date were not reported). On 24-OCT-2017 (reported as "Tuesday night"), she "was up all night" with chills and a fever. Patient stated that, on 25-OCT-2017 (reported as the following day), she also experienced headaches, weakness, tiredness and overall she just "felt horrible and dreadful". Patient also stated the arm where the PNEUMOVAX 23 was administered around the injection site area, her arm was described as "red hot." The patient noted that she was already "immunocompromised" (unknown onset date) prior to the re-vaccination shot on 24-OCT-2017. Patient said her adverse reaction she felt was "systemic" and she primarily wanted to know how long will she continue to experience these side effects because the reactions had not subsided to date. The patient did not received treatment for the events and no laboratory diagnostics were performed. No product quality complaint was involved. Causality assessment between the events and PNEUMOVAX 23 was not reported. The outcome of the first episodes of fever and chills was resolved on an unspecified date. Upon internal review, the event of immunodeficiency was considered to be medically significant.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Physician). The reporter is the patient.  A 73-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 03Jan2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 24Jan2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 14Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 11Feb2022 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing). No known allergies. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results. Therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical information: Paxlovid: start date: 08Jun2022, stop date: 14Jun2022, administrator route - Oral. Relapse on 19Jun2022, 8 days after completing Paxlovid.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: The reported Covid 19 positive after both the doses of  COVID-19 immunization is considered ineffective of BNT162B2, and the Company cannot completely exclude the possible causality between the reported events and BNT162B2 administration.
Chills, shivering, joint pain, headache for approximately two hours 2-4 am, then feverish and nauseous for a few more hours, then about 12 to 14 hours of fatigue with mild chills and sweats.
Significant soreness at injection site; Headache; tiredness; feeling as if in a bubble day of vaccine; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266) via an unspecified route of administration in the right arm on 21Feb2021 at 13:45 (at the age of 26-years-old) as a single dose, for COVID-19 immunization. Medical history included asthma, weakened immune system, and allergy to loratadine (CLARITIN). Prior to vaccination the patient was not diagnosed with COVID-19. Since the vaccination the patient has not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included salbutamol (ALBUTEROL) as needed and fluticasone propionate/ salmeterol xinafoate (ADVAIR 500/50). On 21Feb2021 at 14:15, the patient experienced headache, tiredness and was feeling as if in a bubble the day of vaccine. The next day, on 22Feb2021, the patient experienced significant soreness at injection site. The patient was not treated for headache, tiredness, feeling as if in a bubble the day of vaccine, and significant soreness at injection site. The clinical outcome of headache, tiredness, feeling as if in a bubble the day of vaccine, and significant soreness at injection site was recovering.
After giving last immunization MMR, pt turned pale, had a blank stare, would not respond to moms voice and became limp. I laid her down elevated her feet/legs and began to wash her face. She almost immediately began to respond. Observed her for about 15 minutes. She drank Water and ate crackers before she left (Ambulatory). Mother stated she fainted often as a child, when she was scared, etc. 9/16/06 I spoke with mom today (after school). Mom stated she went to school today and is fine. We have scheduled her next immunizations for 11/20/06.
Itchy; Weakness; Rash is raised; Looks like hives; Rash all over her back, forearm and on her face; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itchy), ASTHENIA (Weakness), RASH PAPULAR (Rash is raised), URTICARIA (Looks like hives) and RASH (Rash all over her back, forearm and on her face) in a 93-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Feb-2021, the patient experienced PRURITUS (Itchy), ASTHENIA (Weakness), RASH PAPULAR (Rash is raised), URTICARIA (Looks like hives) and RASH (Rash all over her back, forearm and on her face). At the time of the report, PRURITUS (Itchy), ASTHENIA (Weakness), RASH PAPULAR (Rash is raised), URTICARIA (Looks like hives) and RASH (Rash all over her back, forearm and on her face) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender who on an unknown date, was vaccinated with a dose of RECOMBIVAX HB (dose and lot # not reported). Concomitant therapies included PEDIARIX. The nurse reported that the patient received a dose of PEDIARIX and a dose of RECOMBIVAX HB Pediatric in error. The patient was indicated to receive PEDVAXHIB instead of RECOMBIVAX HB. The nurse stated that the error occurred during the order entry process. She stated that the error did not occur because of the product's labels; it was because the healthcare provider ordered the wrong vaccine. The patient has not demonstrated any adverse effects. Additional information has been requested.
her nipples very sensitive and erected 3rd dose; vertigo; on and off headaches; dizziness; lymph nodes in the arm of the injection were very sore booster; started to menstruate again 2 days later and it continued; This spontaneous case was reported by a consumer and describes the occurrence of MENSTRUAL DISORDER (started to menstruate again 2 days later and it continued), NIPPLE DISORDER (her nipples very sensitive and erected 3rd dose), VERTIGO (vertigo), DIZZINESS (dizziness) and HEADACHE (on and off headaches) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030h21b, 031a21a and 037a21b) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Vertigo. Concomitant products included VITAMINS NOS for an unknown indication.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Dec-2021, the patient experienced MENSTRUAL DISORDER (started to menstruate again 2 days later and it continued) and LYMPH NODE PAIN (lymph nodes in the arm of the injection were very sore booster). On 08-Dec-2021, the patient experienced DIZZINESS (dizziness). On an unknown date, the patient experienced NIPPLE DISORDER (her nipples very sensitive and erected 3rd dose), VERTIGO (vertigo) and HEADACHE (on and off headaches). At the time of the report, MENSTRUAL DISORDER (started to menstruate again 2 days later and it continued) and HEADACHE (on and off headaches) had not resolved and NIPPLE DISORDER (her nipples very sensitive and erected 3rd dose), VERTIGO (vertigo), DIZZINESS (dizziness) and LYMPH NODE PAIN (lymph nodes in the arm of the injection were very sore booster) outcome was unknown.            Other concomitant medications included supplements.  Treatment information was not provided.   This case was linked to MOD-2021-407147, MOD-2021-407032 (Patient Link).
Pt experienced a headache 5 minutes after injection of first COVID vaccine which lasted approxiamtely 10 minutes. She stated it was located around the right of her temple and moved towards the center of her head. We gave her water and asked her to remove he mask to help with breathing. She rested for an additional 30 minutes. She reported she was then ok and left. When contacted later in the afternoon she reported she was fine.
Information has been received from a physician and a consumer concerning her 48 year old husband with no medical history and an allergy to penicillin, who on 17-OCT-2007 at 09:35 in the am, was vaccinated into the left arm with a first dose of PNEUMOVAX 23. Concomitant medication included a dose of influenza virus vaccine (unspecified) also administered into the left arm. On 18-OCT-2007, the patient experienced a high fever, achy bones, and loss of appetite. The patient sought unspecified medical attention. No laboratory diagnostics studies were performed. Subsequently, the patient recovered. No product quality complaint was involved. Additional information is not expected.
1 HOUR AFTER RECIEVING A SHINGRIX VACCINATION, PATIENT EXPERIENCED EXCRUCIATING PAIN IN THE LEFT JAW UNILATERALLY EXTENDING FROM IN FRONT OF THE LEFT EAR TO THE MIDDLE OF THE FRONT TEETH AND NUMBNESS IN THE BOTTOM LIP. ICE PACK AND ADVIL PROVIDED SOME RELIEF. THE PAIN CONTINUED TO RETURN ABOUT EVERY 3 HOURS. AFTER 2 WEEKS PAIN DEMINISHED IN STRENGHT AND FREQUENCY. NOW IT IS TRIGGERED BY CHEWING AND TALKING. CONTINES TO TREAT WITH ADVIL. 7/31/18- DR, INTERNAL MEDICINE CONSULTATION, DIAGNOSED WITH TRIGEMINAL NEURALGIA/TGN, REFERRED TO NEUROLOGIST. 8/2/18- DR, NEUROLOGIST, CONSULTATION CONFIRMED TGN DIAGNOSED AND ORDERED BRAIN MRI AND MRA. 8/14/18- DR DDS. COSULTATION WITH XRAY OF UPPER MOLARS TAKEN. TGN MAY GO INTO REMISSION BUT DOES NOT GO AWAY. OXCARBAZEPINE PRESCRIBED. NOT TAKING BECAUSE OF POSSIBLE SIDE EFFECTS.
Developed itching & sm amt of swelling of bottom lip-not even visible to others but pt felt;developed approx 30-45 mins after inj. Approx. 10-15 mins later,neck started itching more & throat felt dry.Went to ER for tx.
Patient received a pediatric dose of Hepatitis A vaccine instead of an adult dose. Follow-up Information 03-JUL-2007: Client in the clinic this AM C/O spontaneous onset this AM of facial itching and swelling especially around eyes. Both eyes puffy no rash identified. Advised to use allergy meds or return PRN problems.
Sought emergency room treatment because of swelling, redness, and pain at vaccination site on 04/04/04. Was treated with antibiotics and Benadryl.
Headache, Myalgia, Arthralgia, Fever, Fatigue/ Chills Narrative:
My symptoms began on 12/03/2022 with a tickle in my throat and then a cough and then my throat was sore. I then had sniffles and runny nose. I went to bed and when I woke up, I had a nasty headache and my whole body hurt. I was coughing and sweaty. I tested positive for COVID-19 on 12/04/2022. I lost my voice. I had a fever of 103. I took TYLENOL and then ibuprofen. I called the doctor and had telehealth visit the next day. My fever had not decreased. I slept a lot. I had a severe shortness of breath. I truly felt like I was dying. I received an inhaler, and I got a humidifier for my room. My symptoms began getting better after about 6 days.
flulike symptoms; terrible ringing/hissing in my ears / the hissing and ringing is nonstop,; it feels painful; anxiety.; haven't felt well ever since; feel like / vaccine has permanently ruined me; The patient feel like this vaccine has permanently ruined me and the patient haven't felt well ever since patient's received Shingrix. This case was reported by a consumer and described the occurrence of influenza-like symptoms in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st September 2020, the patient received the 1st dose of Shingrix. In September 2020, less than a day after receiving Shingrix, the patient experienced influenza-like symptoms, ear hissing, ear pain, anxiety, unwell and feeling bad. The patient was treated with methylprednisolone (Medrol). On an unknown date, the outcome of the influenza-like symptoms, ear hissing, ear pain, anxiety, unwell and feeling bad were unknown.   The reporter considered the influenza-like symptoms, ear hissing, ear pain, anxiety, unwell and feeling bad to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received the 1st dose of the Shingrix vaccine. Within four or five hours developed flu like symptoms and a terrible ringing orb hissing in patient's ears. The flu symptoms went away after 3 days but the hissing in patient's ears had been continuous. The patient was prescribed Medrol dose pack which did not help.  Then the patient went to an audiologist and patient's hearing was fine but he agreed that it was caused by this vaccine. The patient haven't felt normal since patient's gotten the Shingrix, the hissing and ringing is nonstop, sometimes it feels painful and was causing horrible anxiety. The patient's read the side effects on Shingrix and there was no mention of tinnitus but after the patient got the shot the handout said to contact patient's doctor immediately if tinnitus occurred.